公司概述
Achieve Life Sciences, Inc. operates as a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline, a plant-based alkaloid designed to assist with nicotine independence in the Canadian, United States, and United Kingdom markets. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, which implies a high degree of scientific risk and reliance on successful clinical trials or regulatory approvals to generate future value. As of the latest available data, the entity maintains a market capitalization of $176.76M and employs a workforce of 28 individuals. The current market capitalization of $176.76M combined with the reported revenue of N/A indicates that the company is in a pre-revenue or early revenue generation phase where valuation is driven primarily by asset value, pipeline potential, and cash reserves rather than historical sales performance or profitability metrics.
财务健康
The financial statements for Achieve Life Sciences, Inc. report a Net Income (TTM) of $-54,648,000 and an EBITDA of $-54,652,000, while revenue figures are listed as N/A. The substantial negative net income in the absence of reported revenue highlights a cost structure dominated by research and development expenses and operational overheads typical of late-stage biotechnology firms that have not yet achieved commercial scale. The company generated a Free Cash Flow of $-28,461,876, indicating a significant cash outflow that limits immediate financial flexibility and necessitates reliance on existing liquidity or external capital raising to sustain operations. Regarding profitability metrics, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, which reflects the accounting treatment of N/A revenue and high fixed costs before any commercial sales volume is realized. On the balance sheet, the company holds $36.40M in cash against $14.96M in debt, resulting in a Debt to Equity ratio of 69.50, which suggests a leveraged position relative to equity but maintains a manageable debt burden given the cash on hand. The Current Ratio stands at 4.39, indicating that the company possesses ample short-term liquid assets to cover its short-term obligations without immediate distress. Finally, the Return on Equity is -257.7% and the Return on Assets is -85.3%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets accumulated, a common characteristic of pre-profitability biotech entities.
估值评估
Valuation multiples for Achieve Life Sciences, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -3.20, where the negative forward P/E implies that the market is pricing in a period of continued earnings contraction or a path to profitability that is not yet reflected in trailing metrics. The Price to Book ratio is 8.22, suggesting that the market values the company's equity at a significant premium over its book value, likely reflecting the intangible value of the cytisinicline asset and potential future commercialization prospects rather than current tangible net worth. Alternative valuation metrics such as the Price to Sales ratio, which is N/A due to lack of revenue, and the EV/EBITDA of -2.84, further indicate that traditional earnings-based valuation models are not currently applicable, forcing reliance on asset-backed or pipeline-based valuation logic. In terms of trading range, the stock has a 52-Week High of $6.03 and a 52-Week Low of $1.84, providing a historical volatility band within which the current share price fluctuates relative to market sentiment. The Beta of 1.96 indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to higher systematic risk compared to large-cap pharmaceutical peers.
Growth & Income
Achieve Life Sciences, Inc. reports Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, as the company has not yet generated sufficient revenue to calculate year-over-year growth rates or has not posted consecutive profitable quarters. Because the growth rates are unavailable and the company is in a loss-making stage, it does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company's strategy focuses on reinvesting its limited Free Cash Flow and cash reserves into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of historical revenue expansion and no current income distribution, with all financial efforts directed toward achieving the commercial milestones necessary to transition from a loss-making biotechnology firm to a profitable pharmaceutical entity.